Abstract
This chapter provides an overview of drug price and reimbursement regulations in Italy within the general context of Italian pharmaceutical policy.
Reimbursement and ex-factory prices are negotiated by the National Drug Agency and the relevant company, whereas the distribution margins and VAT (Value Added Tax) are set by law. The pharmaceutical companies are free to set prices for non-reimbursable (prescription-only and non-prescription) drugs.
Disease burden, comparative risk-benefit profiles and drug budget impacts are the key parameters considered in the negotiation process of ex-factory prices. Many drug price approvals are accompanied by managed market entry contracts, including financially based contracts (e.g., price-volume agreements) and outcome-based contracts (especially for cancer drugs). Generic reference pricing has been applied since 2001, while therapeutic reference pricing, temporarily introduced by regions, has not been allowed since October 2007. Regions, local health authorities and hospital trusts play important roles in managing market access to drugs: despite they cannot change list prices chosen at the national level, they implemented aggressive procurement policies to reduce actual prices and policies aimed at promoting prescribing behavior that favors cheaper drugs.
Pricing policy has doubtlessly improved in the last 20 years (i.e., after the 1993–1994 scandals that revealed that companies, policy makers and top public officials constructed an illegal system to set prices), with a profound cultural change, an increasing role played by evidence-based medicine and, more generally, by technical competence. However, there are some critical factors that should be addressed in the future political agenda. A clearer pathway to defining innovation, increased transparency of assessment and appraisal processes, a more rational distribution of competencies between central and regional authorities, and a softer approach to drug budgets, with an explicit recognition of the impact of drugs in the use (and cost) of other health care services (and vice versa), may further improve the Italian drug pricing policy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The Autonomous Region of Trentino Alto Adige is divided into two Provinces (Trento and Bolzano) that autonomously govern their health care systems. Hence, from the health care system viewpoint, there are 21 “regions.”
- 2.
www.adfsalute.it. Accessed 25 July 2014.
- 3.
www.federfarma.it. Accessed 25 July 2014.
- 4.
- 5.
http://www.agenziafarmaco.gov.it/it/content/registri-farmaci-sottoposti-monitoraggio. Accessed 25 July 2014.
- 6.
http://www.gazzettaufficiale.biz/atti/2013/20130129/13A04712.htm. Accessed 25 July 2014.
References
AIFA (2007) Gruppo di lavoro sull’innovatività dei farmaci. Criteri per l’attribuzione del grado di innovazione terapeutica dei nuovi farmaci ed elementi per la integrazione del dossier per l’ammissione alla rimborsabilità (documento approvato dalla CTS il 10 luglio 2007). http://www.agenziafarmaco.gov.it/allegati/documento_integrale.pdf. AIFA. Accessed 25 July 2014
AIFA (2014) Ossmed. L’uso dei Farmaci in Italia. Rapporto Nazionale Anno 2013–2006. Roma, 2014 and various years. http://www.agenziafarmaco.gov.it/it/content/osservatorio-sull%E2%80%99impiego-dei-medicinali-osmed. Accessed 25 July 2014
Anessi Pessina E, Jommi C, Cantù E (2004) Phasing out market mechanisms in the Italian NHS. Public Money Manag 24(5):309–316
Armeni P, Ferré F (2013) La spesa sanitaria: composizione ed evoluzione. In: CERGAS (ed) Rapporto OASI 2013. Osservatorio sulle Aziende e sul Sistema sanitario Italiano. Egea, Milano, pp 183–221. http://www.cergas.unibocconi.it/. Accessed 25 July 2014
Assosalute (2014) Numeri e Indici dell’Automedicazione, Milano. http://assosalute.federchimica.it/homepage-anifa/pubblicazioni/numeri-e-indici.aspx. Accessed 25 July 2014
Atella V, Schafheutle E, Noyce P, Hassell K (2005) Affordability of medicines and patients’ cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. Appl Health Econ Health Policy 4(1):23–35
Carlson JJ, Sullivan SD, Garrison LP et al (2010) Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3):179–190
Curto S, Ghislandi S, van de Vooren K et al (2014) Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy 116(2–3):182–187
Department of Health (2012) The pharmaceutical price regulation scheme, eleventh report to the parliament. HSMO, Londra. https://www.gov.uk/government/publications/pharmaceutical-price-regulation-scheme-11th-report-to-parliament. Accessed 25 July 2014
Efpia (2011) Patients’ W.A.I.T. indicator. Report. http://www.efpia.eu/documents/33/64/Market-Access-Delays. Accessed 25 July 2014
Farmindustria (2014) Indicatori Farmaceutici, Roma. https://www.farmindustria.it/. Accessed 25 July 2014
Fattore G (1999) Cost-containment and reforms in the Italian National Health Service. In: Mossialos E, Le Grand J (eds) Health care and cost containment in the European Union. Ashgate, Aldershot, pp 513–546
Fattore G, Jommi C (2008) The last decade of Italian pharmaceutical policy: instability or consolidation? Pharmacoeconomics 26:5–15
MEF Ministero dell’Economia e delle Finanze (2014) Documento di Economia e Finanza. http://www.mef.gov.it/doc-finanza-pubblica/def/2014/documenti/DEF_Sezione_II_-_Analisi_e_tendenze_della_finanza_pubblica_.pdf. Accessed 25 July 2014
Fiorio CV, Siciliani L (2010) Co-payments and the demand for pharmaceuticals: evidence from Italy. Special issue on health econometrics. Econ Model 27:835–841
France G, Taroni F (2005) The evolution of health-policy making in Italy. J Health Polit Policy Law 30(1–2):169–187
Garattini L, Ghislandi S (2006) Off-patent drugs in Italy: a short-sighted view? Eur J Health Econ 7(1):79–83
Gehring M, Taylor RS, Mellody M et al (2013) Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study). BMJ Open 3(11):e002957
Ghislandi S, Krulichova I, Garattini L (2005) Pharmaceutical policy in Italy: towards a structural change? Health Policy 72(1):53–73
Ghislandi S, Armeni P, Jommi C (2013) The impact of generic reference pricing in Italy, a decade on. Eur J Health Econ 14(6):959–969
Guerrazzi C, Ricci A (2013) La struttura e le attività del SSN. In: CERGAS (ed) Rapporto OASI 2013. Osservatorio sulle Aziende e sul Sistema sanitario Italiano. Egea, Milano, p 111–181. http://www.cergas.unibocconi.it/. Accessed 25 July 2014
Jommi C, Costa F (2013) I prezzi a ricavo industria dei farmaci rimborsabili: l’Italia a confronto con i principali paesi Ue. Politiche Sanitarie 14(2):55–66
Jommi C, Paruzzolo S (2007) Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case study. Health Policy 81(1):117–130
Jommi C, Cantù E, Anessi Pessina E (2001) New funding arrangements in the Italian National Health Service. Int J Health Plann Manage 6(4):347–368
Jommi C, Costa E, Michelon A et al (2013) Multi-tier drugs assessment in a decentralised health care system. The Italian case-study. Health Policy 112:241–247
Marchetti M, Minghetti P (1992) Italy. In: Spivey RN, Wertheimer AI, Rucker TD (eds) International pharmaceutical services. The drug industry and pharmacy practice in twenty-three major counties of the world. PPP, New York, pp 281–302
Morel T, Arickx F, Befrits G et al (2013) Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis 8:198
Motola D, De Ponti F, Rossi P et al (2005) Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol 59(4):475–478
Russo P, Mennini FS, Siviero PD, Rasi G (2010) Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol 21(10):2081–7
Tediosi F, Gabriele S, Longo F (2009) Governing decentralization in health care under tough budget constraint: what can we learn from the Italian experience? Health Policy 90:303–312
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jommi, C., Minghetti, P. (2015). Pharmaceutical Pricing Policies in Italy. In: Babar, ZUD. (eds) Pharmaceutical Prices in the 21st Century. Adis, Cham. https://doi.org/10.1007/978-3-319-12169-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-12169-7_8
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-12168-0
Online ISBN: 978-3-319-12169-7
eBook Packages: Business and EconomicsEconomics and Finance (R0)